ImmunoBrain Checkpoint (IBC) is a clinical stage biotechnology company at the forefront of transforming the fight against neurodegeneration and aging. They are dedicated to targeting the immune system to restore brain immune communications and enhance natural repair mechanisms. Their lead program focuses on developing a proprietary antibody that targets the inhibitory immune checkpoint pathway, PD-1/PD-L1, to treat Alzheimer's disease.

What sets IBC apart is their unique approach, based on years of groundbreaking research conducted in the lab of Professor Michal Schwartz at the Weizmann Institute of Science. By mobilizing immune cells from the periphery to the brain, IBC aims to cure neurodegenerative diseases and boost neuroprotection and brain function. With a strong scientific platform that highlights the vital role of the peripheral immune system in maintaining brain health, IBC is dedicated to transforming the understanding and treatment of neurodegeneration.

Their cutting-edge therapies, such as the novel antibody targeting PD-L1, have shown promising results in removing neurotoxic proteins, reducing inflammation, and restoring synapses. Driven by a team of world-renowned experts, including Professor Michal Schwartz, ImmunoBrain Checkpoint is poised to revolutionize the field of neuroimmunology and bring innovative solutions to the complex challenges of neurodegenerative diseases